Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Historical Approaches to the Management of MF

May 26th 2022

A brief review of the historical use of systemic therapy in patients who present with myelofibrosis.

Factors in Selecting Therapy for Myelofibrosis

May 26th 2022

Stephen Oh, MD, PhD, highlights the role of transplant in myelofibrosis before Ruben Mesa, MD, discusses factors in selecting systemic therapy.

FDA Places Partial Clinical Hold on Phase 1 Trial Evaluating FHD-286 in Relapsed/Refractory AML and MDS

May 20th 2022

The FDA has placed a partial clinical hold on a phase 1 trial investigating FHD-286 as a treatment for patients with relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome.

Myelofibrosis: Observation and Triggers to Initiate Therapy

May 19th 2022

Expert Pankit Vachhani, MD, breaks down best practices in observation and dictates when it is best to initiated therapy for myelofibrosis.

Risk Assessment and Staging of Myelofibrosis

May 19th 2022

Experts focus on how best to risk stratify and stage myelofibrosis using appropriate diagnostic tools and workup.

Addressing the Challenges in Diagnosing MF

May 12th 2022

Reflections on the predominant challenges one may face while making a differential diagnosis of myelofibrosis.

Making a Differential Diagnosis of Myelofibrosis

May 12th 2022

Shared insight on the differential diagnosis of myelofibrosis, including advice for identifying primary versus secondary disease.

Polycythemia Vera: Ruxolitinib Use and Goals of Therapy

May 5th 2022

A brief discussion on the role of ruxolitinib in the management of polycythemia vera, followed by a review of goals of therapy in this setting.

Treatment Armamentarium for Polycythemia Vera

May 5th 2022

Pankit Vachhani, MD, provides a comprehensive overview of approved agents used to manage patients with polycythemia vera.

Dr. Verstovsek on the Future of ALK2 Inhibitors in Myelofibrosis

May 4th 2022

Srdan Verstovsek, MD, PhD, discusses the future of ALK2 inhibitors in myelofibrosis.

Dr. Mesa on the Future of JAK Inhibitor Therapy in Myelofibrosis

May 4th 2022

Ruben A. Mesa, MD, discusses the future of JAK inhibitor therapy in myelofibrosis.

Dr. Verstovsek on Addressing Anemia in Patients with Myelofibrosis

May 3rd 2022

Srdan Verstovsek, MD, PhD, discusses addressing anemia in patients with myelofibrosis.

Making a Differential Diagnosis of Polycythemia Vera

April 28th 2022

Shared insight on making a differential diagnosis of polycythemia vera and properly risk-stratifying patients who present with this disease.

A Brief Overview of Myeloproliferative Neoplasms

April 28th 2022

Expert Stephen Oh, MD, PhD, provides a broad overview of the myeloproliferative neoplasms: polycythemia vera, essential thrombocythemia, and myelofibrosis.

Momelotinib Shows Promising JAK and ALK2 Inhibition in Myelofibrosis With Anemia

April 26th 2022

Srdan Verstovsek, MD, PhD, discusses the preliminary results of the MOMENTUM study and the potential for ALK2 inhibitor success in the larger anemia treatment landscape.

Dr. Verstovsek on the Mechanism of Action of Momelotinib in Myelofibrosis

April 25th 2022

Srdan Verstovsek, MD, PhD, discusses the mechanisms of action of momelotinib in myelofibrosis.

Targeted Treatment Arsenal for Myelofibrosis Set to Explode

April 22nd 2022

Ruben Mesa, MD, Jamile M. Shammo, MD, FASCP, FACP, Angela G. Fleischman, MD, PhD, and Stephen T. Oh, MD, PhD discuss the emerging treatment landscape in myelofibrosis.

Pacritinib May Fill Unmet Symptom Burden Need for Patients With Myelofibrosis With Moderate/Severe Thrombocytopenia

April 15th 2022

Physical function-related symptoms were prominent in the symptom burden of adult patients with myelofibrosis and moderate or severe thrombocytopenia, according to a retrospective analysis of the phase 3 PERSIST-2 study.

Combination Navitoclax and Ruxolitinib Elicits Improved Bone Marrow Fibrosis in Myelofibrosis

April 12th 2022

Navitoclax plus ruxolitinib produced an improvement in bone marrow fibrosis and a reduction in variant allele frequency in patients with myelofibrosis who progressed on or had suboptimal response with prior ruxolitinib monotherapy.

FDA Lifts Partial Clinical Hold Placed on Studies Evaluating Magrolimab in MDS and AML

April 12th 2022

The FDA has lifted a partial clinical hold that had been placed on studies examining magrolimab in combination with azacitidine following a review of comprehensive safety data collected from each trial.